Literature DB >> 11251880

T-cell enforced invariance of the antibody repertoire in the immune response against a bacterial carbohydrate antigen.

A Rademaekers1, C Specht, E Kölsch.   

Abstract

The humoral response against the bacterial polysaccharide antigen alpha(1-->3) dextran (Dex) is controlled by J558 idiotype-(Id) specific T cells. These T cells of which the cell clone 178-4 Ts is a representative by all relevant criteria, recognize J558 Id-bearing B cells in an I-Ed-restricted manner. Costimulation via CD28/B7-1 but not via CD40/CD40L leads to T-cell activation. These T cells do not only suppress B cells producing the immunoglobulin (Ig)G3 isotype but also support the survival and clonal expansion of J558 Id positive B cells both in vivo and in vitro. This T-cell mediated dominance of the J558 idiotype limits the appearance of antibodies carrying other more diverse idiotypes which appear in immunized BALB/c nu/nu mice where no regulatory T cells occur. This T-cell mediated antibody invariance could be a strategy of the immune system responding to highly conserved antigens like polysaccharides, different from those against protein antigens, where diversity is assumed to be the basis for a successful response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11251880     DOI: 10.1046/j.1365-3083.2001.00864.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  2 in total

1.  Immunoglobulin class switching appears to be regulated by B-cell antigen receptor-specific T-cell action.

Authors:  Hans Lange; Oliver Hecht; Michael Zemlin; Ahmad Trad; Radu I Tanasa; Harry W Schroeder; Hilmar Lemke
Journal:  Eur J Immunol       Date:  2012-04       Impact factor: 5.532

2.  Clonal Progression during the T Cell-Dependent B Cell Antibody Response Depends on the Immunoglobulin DH Gene Segment Repertoire.

Authors:  Ahmad Trad; Radu Iulian Tanasa; Hans Lange; Michael Zemlin; Harry W Schroeder; Hilmar Lemke
Journal:  Front Immunol       Date:  2014-08-11       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.